1. Academic Validation
  2. Combined modifications of mexiletine pharmacophores for new lead blockers of Na(v)1.4 channels

Combined modifications of mexiletine pharmacophores for new lead blockers of Na(v)1.4 channels

  • Biophys J. 2013 Jan 22;104(2):344-54. doi: 10.1016/j.bpj.2012.11.3830.
Michela De Bellis 1 Annamaria De Luca Jean F Desaphy Roberta Carbonara Judith A Heiny Ann Kennedy Alessia Carocci Maria M Cavalluzzi Giovanni Lentini Carlo Franchini Diana Conte Camerino
Affiliations

Affiliation

  • 1 Unit of Pharmacology, Department of Pharmacy-Drug Science, University of Bari, Aldo Moro, Italy.
Abstract

Previously identified potent and/or use-dependent mexiletine (Mex) analogs were used as template for the rational design of new Na(v)-channel blockers. The effects of the novel analogs were tested on sodium currents of native myofibers. Data and molecular modeling show that increasing basicity and optimal alkyl chain length enhance use-dependent block. This was demonstrated by replacing the amino group with a more basic guanidine one while maintaining a proper distance between positive charge and aromatic ring (Me13) or with homologs having the chirality center nearby the amino group or the aromatic ring. Accordingly, a phenyl group on the asymmetric center in the homologated alkyl chain (Me12), leads to a further increase of use-dependent behavior versus the phenyl Mex derivative Me4. A fluorine atom in paraposition and one ortho-methyl group on the xylyloxy ring (Me15) increase potency and stereoselectivity versus Me4. Charge delocalization and greater flexibility of Me15 may increase its affinity for Tyr residues influencing steric drug interaction with the primary Phe residue of the binding site. Me12 and Me15 show limited selectivity against Na(v)-isoforms, possibly due to the highly conserved binding site on Na(v). To our knowledge, the new compounds are the most potent Mex-like Na(v) blockers obtained to date and deserve further investigation.

Figures
Products